KRSA · NASDAQ
Korsana Biosciences (KRSA) Stock Price & Fundamentals
Korsana Biosciences (KRSA) closed at $477.15 on Oct 9, 2026, down 0.87% from the previous close of $481.33.
Share price, past year
1Y +9.50%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $477.15 |
| Sep 30, 2026 | $482.47 |
| Aug 31, 2026 | $486.97 |
| Jul 31, 2026 | $472.65 |
| Jun 30, 2026 | $444.08 |
| May 29, 2026 | $440.43 |
| Apr 30, 2026 | $424.10 |
| Mar 31, 2026 | $423.93 |
| Feb 27, 2026 | $436.76 |
| Jan 30, 2026 | $449.67 |
| Dec 31, 2025 | $478.96 |
| Nov 28, 2025 | $469.19 |
| Oct 31, 2025 | $457.15 |
Key statistics
- Market cap
- $2.03B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.61
- Revenue (TTM)
- $1.99M
- Net income (TTM)
- −$6.71M
- Shares outstanding
- 4.3M
- Dividend yield
- —
- 52-week range
- $408.95 – $496.59
Korsana Biosciences's market cap is $2.03B, based on a share price of $477.15 and 4.3M shares outstanding as of Jun 30, 2026.
Financials
Korsana Biosciences reported revenue of $2.07M for fiscal 2025, up 3.70% from fiscal 2024.
Korsana Biosciences reported a net loss of $3.53M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $2.07M | +3.7% | −$3.53M | −170.1% | −$1.11 | — |
| FY2024ended Dec 31, 2024 | $2.00M | — | −$3.06M | −152.9% | −$1.21 | — |
| FY2023ended Dec 31, 2023 | $0.00 | −100.0% | −$5.26M | — | −$2.25 | — |
| FY2022ended Dec 31, 2022 | $297.00K | −92.5% | −$44.08M | −14,841.1% | −$20.28 | −$40.61M |
| FY2021ended Dec 31, 2021 | $3.94M | +71.7% | −$51.65M | −1,310.2% | −$1.32 | −$36.52M |
| FY2020ended Dec 31, 2020 | $2.30M | −49.1% | −$77.80M | −3,388.6% | −$2.56 | −$74.01M |
| FY2019ended Dec 31, 2019 | $4.51M | — | −$123.01M | −2,729.3% | −$4.49 | −$109.10M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2026ended Mar 31, 2026 | $0.00 | −$3.18M | −$0.76 |
| Q4 FY2025ended Dec 31, 2025 | $1.03M | −$799.00K | −$0.14 |
| Q3 FY2025ended Sep 30, 2025 | $875.00K | −$976.00K | −$0.30 |
| Q2 FY2025ended Jun 30, 2025 | $93.00K | −$324.00K | −$0.11 |
| Q1 FY2025ended Mar 31, 2025 | $81.00K | −$1.43M | −$0.56 |
| Q4 FY2024ended Dec 31, 2024 | $1.81M | $530.00K | $0.23 |
| Q3 FY2024ended Sep 30, 2024 | $194.00K | −$723.00K | −$0.29 |
| Q2 FY2024ended Jun 30, 2024 | $0.00 | — | — |
Company profile
- Name
- Korsana Biosciences, Inc.
- Ticker
- KRSA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 203 Crescent Street, Bldgs. #3/3a/4, Suite 503, Waltham, MA 02453
- Incorporated in
- MA
- Fiscal year ends
- December
- SEC CIK
- 0001755237
Recent SEC filings
- Sep 11, 2026
- Aug 27, 2026
- Aug 25, 2026
- Aug 4, 2026
- May 12, 2026
- Apr 30, 2026
- Apr 1, 2026
- Mar 30, 2026
Frequently asked questions
What is Korsana Biosciences's stock price?
Korsana Biosciences (KRSA) closed at $477.15 on Oct 9, 2026, down 0.87% from the previous close of $481.33.
What is Korsana Biosciences's market cap?
Korsana Biosciences's market cap is $2.03B, based on a share price of $477.15 and 4.3M shares outstanding as of Jun 30, 2026.
How much revenue does Korsana Biosciences make?
Korsana Biosciences reported revenue of $2.07M for fiscal 2025, up 3.70% from fiscal 2024.
Does Korsana Biosciences pay a dividend?
Korsana Biosciences's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Korsana Biosciences, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures